相关实验视频
Updated: Jan 11, 2026

12:09
Studying Food Reward and Motivation in Humans
Published on: March 19, 2014
24.1K
GLP-1受体激活剂和研究治疗过度进食和物质使用障碍
Jingchuan Guo1, Matthew R Hayes2, Lorenzo Leggio3
1Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida 32610.
概括
葡萄糖类-1受体 (GLP-1R) 激动剂显示出超出糖尿病和肥胖症的前景. 这些药物向大脑受体,为成行为提供潜在的治疗方法,如过度饮食和物质使用障碍.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 激动剂已成为2型糖尿病和肥胖症的治疗方法.
- 新兴研究表明GLP-1R激动剂具有更广泛的治疗应用.
- 这些激动剂对外围组织和中枢神经系统的受体起作用.
研究的目的:
- 审查GLP-1R激动剂不断扩大的治疗潜力.
- 探索GLP-1R激动剂在治疗病理性消费行为中的作用.
- 巩固基础科学,临床数据和现实世界观察的发现.
主要方法:
- 使用动物模型进行的临床前研究的审查.
- 对人类临床试验数据的分析.
- 综合现实世界的观测证据.
主要成果:
- GLP-1R激动剂有效地穿越血脑屏障,参与中央受体.
- 证据支持GLP-1R激动剂在治疗过度饮食障碍方面的有效性.
- GLP-1R激动剂在治疗酒精和其他物质使用障碍方面表现出潜力.
结论:
- GLP-1R激动剂代表了一系列行为障碍的有前途的治疗类.
- 针对大脑中的GLP-1R提供了一种新的成治疗策略.
- 需要在行为健康方面进一步研究和临床应用GLP-1R激动剂.
相关概念视频
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
G Protein-coupled Receptors
16.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.4K
Oral Hypoglycemic Agents: Glinides
577
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
577
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
511
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
511
Drug-Receptor Interaction: Agonist
3.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.8K

